Pre-profit biotechs on Hong Kong exchange, STAR board could see investment influx via Stock Connect expansion 

Pre-profit biotechs listed on the Hong Kong stock exchange or Shanghai’s STAR board could soon see an influx of investment as the Chinese government expands the Stock Connect channel linking financial markets between Hong Kong and the mainland. 

In an annual policy address on Wednesday, Hong Kong Chief Executive Carrie Lam said Chinese authorities have agreed to “accelerate the pace of inclusion” of HKEX- or STAR-listed biotechs in Stock Connect, an investment channel that enables mainland investors to purchase shares listed on the Hong Kong exchange and international investors to trade stocks on mainland exchanges. ...